Alterity Therapeutics Ltd
ATHE3.090USD
+0.060+1.98%
收盤 12/19, 16:00（美東）報價延遲15分鐘
47.01M總市值
虧損本益比TTM
關於 Alterity Therapeutics Ltd 公司
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd簡介
公司代碼ATHE
公司名稱Alterity Therapeutics Ltd
上市日期Mar 28, 2000
CEOStamler (David A)
員工數量9
證券類型Depository Receipt
年結日Mar 28
公司地址Level 14, 350 Collins Street
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編3000
電話61393494906
網址https://alteritytherapeutics.com/
公司代碼ATHE
上市日期Mar 28, 2000
CEOStamler (David A)
Alterity Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
其他
98.23%
持股股東
持股股東
佔比
Twin Lakes Capital
0.77%
Morgan Stanley & Co. LLC
0.38%
Homrich Berg
0.32%
Greenleaf Trust
0.18%
Citadel Advisors LLC
0.12%
其他
98.23%
股東類型
持股股東
佔比
Private Equity
0.77%
Research Firm
0.42%
Investment Advisor/Hedge Fund
0.36%
Bank and Trust
0.18%
Hedge Fund
0.12%
其他
98.16%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
31
335.79K
1.62%
--
2025Q3
31
335.79K
1.62%
+112.77K
2025Q2
26
223.02K
2.05%
-19.87K
2025Q1
25
242.89K
2.06%
+14.64K
2024Q4
25
125.45K
2.26%
+11.61K
2024Q3
25
113.89K
1.99%
+34.70K
2024Q2
24
79.19K
2.01%
-15.98K
2024Q1
24
95.17K
1.68%
-51.08K
2023Q4
23
88.25K
2.56%
+29.17K
2023Q3
26
59.08K
3.01%
-573.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Twin Lakes Capital
5.92K
0.03%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
58.23K
0.32%
+14.60K
+33.46%
Jun 30, 2025
Homrich Berg
--
0%
-37.48K
-100.00%
Jun 30, 2025
Greenleaf Trust
17.00K
0.09%
+17.00K
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
8.19K
0.05%
-1.56K
-16.02%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
Aug 31, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
公告日期
類型
比率
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
常見問題
Alterity Therapeutics Ltd的前五大股東是誰？
Alterity Therapeutics Ltd的前五大股東如下：
Twin Lakes Capital持有股份：5.92K佔總股份比例：0.03%。
Morgan Stanley & Co. LLC持有股份：58.23K佔總股份比例：0.32%。
Homrich Berg持有股份：0.00佔總股份比例：0.00%。
Greenleaf Trust持有股份：17.00K佔總股份比例：0.09%。
BNP Paribas Securities Corp. North America持有股份：8.19K佔總股份比例：0.05%。
Twin Lakes Capital持有股份：5.92K佔總股份比例：0.03%。
Morgan Stanley & Co. LLC持有股份：58.23K佔總股份比例：0.32%。
Homrich Berg持有股份：0.00佔總股份比例：0.00%。
Greenleaf Trust持有股份：17.00K佔總股份比例：0.09%。
BNP Paribas Securities Corp. North America持有股份：8.19K佔總股份比例：0.05%。
Alterity Therapeutics Ltd的前三大股東類型是什麼？
Alterity Therapeutics Ltd 的前三大股東類型分別是：
Twin Lakes Capital
Morgan Stanley & Co. LLC
Homrich Berg
Twin Lakes Capital
Morgan Stanley & Co. LLC
Homrich Berg
有多少機構持有Alterity Therapeutics Ltd(ATHE)的股份？
截至2025Q4，共有31家機構持有Alterity Therapeutics Ltd的股份，合計持有的股份價值約為335.79K，占公司總股份的1.62% 。與2025Q3相比，機構持股有所增加，增幅為--。
哪個業務部門對Alterity Therapeutics Ltd的收入貢獻最大？
在--，--業務部門對Alterity Therapeutics Ltd的收入貢獻最大，創收--，占總收入的--% 。
